Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency

被引:56
|
作者
Atkinson, Rachel L. [1 ]
Yang, Wei T. [2 ]
Rosen, Daniel G. [6 ]
Landis, Melissa D. [7 ]
Wong, Helen [7 ]
Lewis, Michael T. [5 ]
Creighton, Chad J. [5 ]
Sexton, Krystal R. [5 ]
Hilsenbeck, Sue G. [5 ]
Sahin, Aysegul A. [4 ]
Brewster, Abenaa M. [1 ]
Woodward, Wendy A. [3 ]
Chang, Jenny C. [7 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Imaging, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[5] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA
[6] Baylor Coll Med, Houston, TX 77030 USA
[7] Methodist Hosp, Res Inst, Houston, TX 77030 USA
关键词
RISK-FACTORS; PREGNANCY; IDENTIFICATION; EPIDEMIOLOGY; MOUSE; MODEL;
D O I
10.1186/bcr3471
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: We hypothesized that cells present in normal tissue that bear cancer stem cell markers may represent a cancer cell of origin or a microenvironment primed for tumor development, and that their presence may correlate with the clinically defined subtypes of breast cancer that show increased tumorigenicity and stem cell features. Methods: Normal tissues sampled at least 5 cm from primary tumors (normal adjacent tissue) were obtained from 61 chemotherapy-naive patients with breast cancer treated with mastectomy. Samples were stained simultaneously with immunofluorescence for CD44/CD49f/CD133/2 stem cell markers. We assessed the association between CD44+ CD49f+ CD133/2+ staining in normal adjacent tissue and breast cancer receptor subtype (defined by the expression of the estrogen (ER), progesterone (PR), or human epidermal growth factor-2 (Her2) receptors). We also examined the correlation between CD44+ CD49f+ CD133/2+ immunofluorescence and each of two previously published gene signatures, one derived from stem-cell enriched tissue and one from BRCA mutated tissue expected to have defective DNA repair. Results: Patients with triple negative breast cancer (ER -/PR -/HER2 -) expressed CD44+ CD49f+ CD133/2+ in 9 of 9 normal adjacent tissue samples compared with 7 of 52 ER+ and/or Her2+ tumors (P < 0.001). Further, expression of CD44+ CD49f+ CD133/2+ by normal adjacent tissue correlated positively with a stem cell-derived tumorigenic signature (P < 0.001) and inversely with a defective DNA-repair signature (P < 0.001). Conclusion: Normal cells bearing cancer stem cell markers are associated with the triple negative receptor subtype of breast cancer. This study suggests stem cell staining and gene expression signatures from normal breast tissues represent novel tissue-based risk biomarkers for triple negative breast cancer. Validation of these results in additional studies of normal tissue from cancer-free women could lay the foundation for future targeted triple negative breast cancer prevention strategies.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Genetic Markers in Triple-Negative Breast Cancer
    Sporikova, Zuzana
    Koudelakova, Vladimira
    Trojanec, Radek
    Hajduch, Marian
    CLINICAL BREAST CANCER, 2018, 18 (05) : E841 - E850
  • [42] Homologous recombination deficiency in triple negative breast cancer
    Belli, Carmen
    Duso, Bruno Achutti
    Ferraro, Emanuela
    Curigliano, Giuseppe
    BREAST, 2019, 45 : 15 - 21
  • [43] Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair
    Matta, Jaime
    Ortiz, Carmen
    Encarnacion, Jarline
    Dutil, Julie
    Suarez, Erick
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
  • [44] Heterogeneity Within the Cancer Stem Cell Population of the Triple-negative Breast Cancer Subtype
    Ehmsen, S.
    Christensen, A. G.
    Ditzel, H. D.
    Leth-Larsen, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S115 - S116
  • [45] The Adipokine Visfatin Modulates Cancer Stem Cell Properties in Triple-Negative Breast Cancer
    Chiang, Yi-Fen
    Huang, Ko-Chieh
    Chen, Hsin-Yuan
    Huang, Tsui-Chin
    Ali, Mohamed
    Chang, Hsin-Yi
    Shieh, Tzong-Ming
    Shih, Yin-Hwa
    Wang, Kai-Lee
    Huang, Yun-Ju
    Chung, Cheng-Pei
    Hsia, Shih-Min
    BIOMEDICINES, 2023, 11 (02)
  • [46] Cancer stem cell (CSC) and epithelial mesenchymal transition (EMT) in triple negative breast cancer
    Ishikawa, Y.
    Oyama, T.
    Katayama, A.
    Handa, T.
    Tokiniwa, H.
    Horiguchi, J.
    Iino, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S123 - S123
  • [47] Identification of cancer stem cell antigens revealed unique characteristics of triple negative breast cancer
    Torigoe, Toshihiko
    Hirohashi, Yoshihiko
    Takahashi, Akari
    Asanuma, Hiroko
    Nakatsugawa, Munehide
    Inoda, Satoko
    Sato, Noriyuki
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 24 : S53 - S53
  • [48] DNA repair signature is associated with anthracycline response in triple negative breast cancer patients
    Rodriguez, A. A.
    Makris, A.
    Wu, M. F.
    Rimawi, M.
    Froehlich, A.
    Dave, B.
    Hilsenbeck, S. G.
    Chamness, G. C.
    Lewis, M. T.
    Dobrolecki, L. E.
    Jain, D.
    Sahoo, S.
    Osborne, C. K.
    Chang, J. C.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (01) : 189 - 196
  • [49] DNA repair signature is associated with anthracycline response in triple negative breast cancer patients
    A. A. Rodriguez
    A. Makris
    M. F. Wu
    M. Rimawi
    A. Froehlich
    B. Dave
    S. G. Hilsenbeck
    G. C. Chamness
    M. T. Lewis
    L. E. Dobrolecki
    D. Jain
    S. Sahoo
    C. K. Osborne
    J. C. Chang
    Breast Cancer Research and Treatment, 2010, 123 : 189 - 196
  • [50] Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
    Park, So-Yeon
    Choi, Jang-Hyun
    Nam, Jeong-Seok
    CANCERS, 2019, 11 (07)